These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 18685459)

  • 41. Nonalcoholic fatty liver disease as a feature of the metabolic syndrome.
    Socha P; Wierzbicka A; Neuhoff-Murawska J; Włodarek D; Podleśny J; Socha J
    Rocz Panstw Zakl Hig; 2007; 58(1):129-37. PubMed ID: 17711101
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Obesity and non-alcoholic steatohepatitis].
    Méndez-Sánchez N; Chávez-Tapia NC; Uribe M
    Gac Med Mex; 2004; 140 Suppl 2():S67-72. PubMed ID: 15641474
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Non-alcoholic fatty liver disease in children: a new complication of obesity].
    Bocca G; Stolk RP; Scheenstra R; Sauer PJ
    Ned Tijdschr Geneeskd; 2008 Nov; 152(45):2443-7. PubMed ID: 19051794
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis.
    Anderson N; Borlak J
    Pharmacol Rev; 2008 Sep; 60(3):311-57. PubMed ID: 18922966
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Non-alcoholic fatty liver disease pathogenesis: the present and the future.
    Petta S; Muratore C; Craxì A
    Dig Liver Dis; 2009 Sep; 41(9):615-25. PubMed ID: 19223251
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficiency of intermittent exercise on adiposity and fatty liver in rats fed with high-fat diet.
    Sene-Fiorese M; Duarte FO; Scarmagnani FR; Cheik NC; Manzoni MS; Nonaka KO; Rossi EA; de Oliveira Duarte AC; Dâmaso AR
    Obesity (Silver Spring); 2008 Oct; 16(10):2217-22. PubMed ID: 18719640
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C.
    Rafiq N; Younossi ZM
    Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):207-15. PubMed ID: 19072356
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fitness versus fatness: moving beyond weight loss in nonalcoholic fatty liver disease.
    Johnson NA; George J
    Hepatology; 2010 Jul; 52(1):370-81. PubMed ID: 20578153
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nonalcoholic fatty liver disease: emerging mechanisms and consequences.
    Turkish AR
    Curr Opin Clin Nutr Metab Care; 2008 Mar; 11(2):128-33. PubMed ID: 18301087
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diagnosis and therapy of nonalcoholic steatohepatitis.
    Torres DM; Harrison SA
    Gastroenterology; 2008 May; 134(6):1682-98. PubMed ID: 18471547
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Alcoholic and nonalcoholic steatohepatitis: the same disease! II. Management].
    Spahr L; Hadengue A
    Rev Med Suisse; 2005 Sep; 1(31):2032-4. PubMed ID: 16212005
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia.
    Hyogo H; Tazuma S; Arihiro K; Iwamoto K; Nabeshima Y; Inoue M; Ishitobi T; Nonaka M; Chayama K
    Metabolism; 2008 Dec; 57(12):1711-8. PubMed ID: 19013295
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Alcoholic and nonalcoholic forms of fatty liver disease.
    Forgione A; Miele L; Cefalo C; Gasbarrini G; Grieco A
    Minerva Gastroenterol Dietol; 2007 Mar; 53(1):83-100. PubMed ID: 17415346
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current concepts in the pathogenesis of nonalcoholic fatty liver disease.
    Méndez-Sánchez N; Arrese M; Zamora-Valdés D; Uribe M
    Liver Int; 2007 May; 27(4):423-33. PubMed ID: 17403181
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver disease.
    Morgan K; Uyuni A; Nandgiri G; Mao L; Castaneda L; Kathirvel E; French SW; Morgan TR
    Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):843-54. PubMed ID: 18794597
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Insulin resistance, inflammation, and non-alcoholic fatty liver disease.
    Tilg H; Moschen AR
    Trends Endocrinol Metab; 2008 Dec; 19(10):371-9. PubMed ID: 18929493
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nonalcoholic fatty liver disease: diagnosis and management.
    Wilkins T; Tadkod A; Hepburn I; Schade RR
    Am Fam Physician; 2013 Jul; 88(1):35-42. PubMed ID: 23939604
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Nonalcoholic steatohepatitis (NASH): therapeutic approaches].
    Buscher HP
    Dtsch Med Wochenschr; 2004 Sep; 129 Suppl 2():S60-2. PubMed ID: 15368170
    [No Abstract]   [Full Text] [Related]  

  • 59. The trials and tribulations of the treatment of nonalcoholic fatty-liver disease.
    Gan SK; Adams LA; Watts GF
    Curr Opin Lipidol; 2008 Dec; 19(6):592-9. PubMed ID: 18957882
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management of nonalcoholic steatohepatitis: an evidence-based approach.
    Mahady SE; George J
    Clin Liver Dis; 2012 Aug; 16(3):631-45. PubMed ID: 22824485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.